Major institutional asset management firms like BlackRock periodically adjust their portfolio holdings in micro-cap and small-cap biotechnology equities like Tonix Pharmaceuticals based on passive index fund rebalancing, quantitative screening metrics, and institutional risk parameters. While large asset managers occasionally hold minor fractional stakes through exchange-traded funds or passive index tracking portfolios, their ownership percentages in highly volatile clinical-stage biopharmaceutical stocks fluctuate frequently and represent negligible fractions of their massive global assets under management.